Steris Q2 adjusted EPS beats; fiscal 2027 outlook lifted

Overview

• The infection prevention firm's fiscal Q2 revenue rose 9% yr/yr, with 8% organic growth

• Adjusted EPS for fiscal Q2 rose and beat analyst expectations

• Company raised fiscal 2027 adjusted EPS outlook, citing solid performance and tariff refunds

Outlook

• Company expects fiscal 2027 revenue growth of 7-8% as reported, 6-7% organic

• STERIS raises fiscal 2027 adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30

Result Drivers

• LIFE SCIENCES GROWTH - Co said Life Sciences segment revenue rose 18%, led by 53% growth in capital equipment and higher consumables and service revenue

• TARIFF REFUNDS - Co said tariff refunds provided a $20 mln pre-tax benefit to quarterly results

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for STERIS plc is $269.50, about 16.5% above its November 3 closing price of $231.35

Reuters Recommended Reads

• Nov 4 - UK's Smith & Nephew misses Q3 revenue estimates, cuts outlook on slower US orthopaedics market

• Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength

• Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)